4882 — Perseus Proteomics Income Statement
0.000.00%
- ¥5bn
- ¥3bn
- ¥120m
Annual income statement for Perseus Proteomics, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 67.9 | 71.9 | 94.2 | 100 | 120 |
| Cost of Revenue | |||||
| Gross Profit | 64.1 | 67.7 | 86.5 | 87.7 | 104 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 481 | 660 | 887 | 1,218 | 1,019 |
| Operating Profit | -413 | -588 | -793 | -1,118 | -899 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -411 | -597 | -785 | -1,103 | -902 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -413 | -599 | -787 | -1,104 | -905 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -413 | -599 | -787 | -1,104 | -905 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -413 | -599 | -787 | -1,104 | -905 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -35.3 | -44.6 | -61.6 | -81.4 | -60.1 |
| Dividends per Share |